Avoidable accumulation of potentially toxic levels of benzothiazoles in babies receiving intravenous therapy.
Large amounts of a compound of exogenous origin were present in the serum of premature babies receiving prolonged intravenous therapy. This compound, identified as 2-(carboxymethylthio)benzothiazole (CMB) is derived from oxidation of 2-(hydroxyethylthio)benzothiazole which is leached out of rubber components of intravenous administration sets and syringes. Serum concentrations of CMB after prolonged exposure can exceed 500 mumol/l; concentrations over 35 mumol/l were observed in 91 babies over a period of twenty-seven months. This potentially toxic accumulation can be largely avoided by judicious choice of equipment.